Combining antiangiogenic (DC101) therapy with anti–VEGFR-1 (6.12) antibody, chemotherapy, or RTX therapy enhances antitumor effects. NOD/SCID mice engrafted with subcutaneous human lymphoma xenografts were treated with antibodies through intraperitoneal injection for 3 weeks. Comparison of results on treatment day 21 is shown. (A) Tumor growth curves of RL lymphoma xenografts treated with immunoglobulin (IVIG), anti–human VEGFR-1 (6.12), anti–murine VEGFR-2 (DC101), or both antibodies (6.12 + DC101) (n = 9-16 mice/group). Results were statistically significant (P < .05) for 6.12 vs 6.12 + DC101 on days 16 to 21 and for DC101 vs 6.12 + DC101 on days 18 to 21. (B) Tumor growth curves of RL lymphoma xenografts treated with immunoglobulin (IVIG), maximally tolerated MTX, DC101, or MTX + DC101 (n = 8-10 mice/group). Results were statistically significant (P < .05) for IVIG compared with MTX + DC101 on days 4 to 21 and for DC101 compared with MTX + DC101 on days 16, 18, and 21. (C) Tumor growth curves of SKI-DLBCL1 lymphoma xenografts treated with IVIG, RTX, DC101, and RTX + DC101 (n = 10 mice/group). Results were statistically significant (P < .05) for DC101 compared with RTX + DC101 and for RTX vs RTX + DC101 on days 19 to 21. Error bars indicate standard error of mean tumor volume.